Trump Order Spurs Debate Over Vaccine Makers' Fortunes

President Donald Trump recently announced an executive order to change the number and timing of vaccines recommended for children. The order has left analysts wondering about its potential impact on vaccine makers, particularly companies like Merck & Co., Inc. (MRK) and GSK.

The executive order aims to reduce the number of vaccinations required for children, which could potentially lead to increased sales for these vaccine manufacturers. However, Stephen Ayers from ALLKA Research notes that this might not necessarily translate into higher profits for these companies.

On August 22, 2026, analysts at Seeking Alpha weighed in on the potential implications of Trump's executive order on vaccine makers. Gen Alpha commented that while the change could lead to increased demand for certain vaccines, it may also create uncertainty and potentially reduce sales for other vaccines.